iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call on August 12, 2021, at 8:00 a.m. ET to report its second quarter 2021 financial results and offer a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call on August 12, 2021, at 8:00 a.m. ET to report its second quarter 2021 financial results and offer a corporate update. The event will be accessible via a pre-registration link and a live audio webcast available on the company's investor relations website. iTeos is focused on immuno-oncology therapeutics with ongoing trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Preliminary data indicates potential clinical activity and favorable tolerability for both candidates.
Positive
- Ongoing Phase 1 clinical trial of EOS-448 showing preliminary clinical activity and favorable tolerability.
- Advancing inupadenant in clinical development; preliminary results suggest encouraging single-agent activity.
Negative
- None.
Details
News Market Reaction – ITOS
The recorded move for ITOS in the trading session of this news was +0.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Thursday, August 12, 2021 to report its second quarter 2021 financial results and provide a corporate update.
To pre-register for the call, please use the following link, and you will receive access details via email.
Webcast
This registration link, along with a live audio webcast, will be accessible from the Events page of the Company’s IR website at https://investors.iteostherapeutics.com/news-and-events/events. A replay will be available on the Company’s website approximately two hours after completion of the event and for 30 days following the call
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.